Synergistic Interactions between a KCNQ Channel Opener and an Opioid: flupirtine and morphine in rat pain models including neuropathic pain

C S Goodchild ^{1, 2}, A Kolosov ^1,2, AP Tucker ¹ , Ray Nadeson ¹ and Ian Cooke ²
1 Department of Anaesthesia and Perioperative Medicine, Monash Institute of Medical Research, Monash University, Clayton Victoria, Australia 3168
2 CNSBio Ltd Pty Ltd, Floor 15, 1 Nicholson St, Melbourne, Victoria, Australia 3000

Purpose of Study

Flupirtine is an established clinical analgesic for mild to moderate musculoskeletal pain states. It has recently been shown to be a KCNQ 2-3 potassium channel opener. These experiments were performed to see if this property could be useful in treating more severe pain states characterized by central sensitisation with the drug either given alone or in combination with morphine.

Method

Experiments were performed in rats in an observer blinded fashion with vehicle controls. Non sedating doses of flupirtine, morphine and combinations containing both drugs were defined using the rotarod technique. Dose response relationships were determined for non sedating doses of both drugs given alone and together in combination in causing antinociception in three nociception paradigms : electrical pain; carrageenan paw inflammation; streptozotocin-induced diabetic neuropathy.

Result

Flupirtine and morphine when given alone caused slight to moderate antinociception in all three paradigms. Flupirtine also caused significant increases in morphine antinociception in all three models. In carrageenan paw inflammation complete reversal of carrageenan-induced hyperalgesia was caused by 10 mg/kg flupirtine in combination with 0.4 mg/kg morphine. These doses of the two drugs were ineffective when given alone but the combination caused complete antinociception in this model of neuropathic pain. In the diabetic neuropathy model (see figure)morphine 3.2 mg/kg given alone caused significant antinociception but the size of that response were significantly less than that caused by a lower dose of morphine (1.6 mg/kg shown to be ineffective when it was given alone) given in combination with flupirtine 10 mg/kg (p < 0.001; one way ANOVA).

Conclusion

Flupirtine should be investigated as an adjunct analgesic with opioids for the management of patients with severe pain states involving central sensitisation.

Time of Presentation
0830